|
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We conclude that structural variants in the RAR/RXR and NURR1 genes do not play a major role in the etiology of schizophrenia.
|
15635645 |
2005 |
|
Human papilloma virus infection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate: (1) the promoter methylation status of DAPK1, RAR-β2 and MGMT in randomly selected normal cytology of the general female population; (2) the effectiveness of gene methylation in liquid-based cytology to help in the early diagnosis of HSIL; (3) the relationship between HPV infection and gene methylation.
|
22116316 |
2012 |
|
Congenital absence of kidney
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic investigations have identified several gene variants that cause RA, including <i>EYA1</i>, <i>LHX1</i>, and <i>WT1</i> However, whereas compound null mutations of genes encoding α and γ retinoic acid receptors (RARs) cause RA in mice, to date there have been no reports of variants in RAR genes causing RA in humans.
|
28739660 |
2017 |
|
Refractory cancer
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
|
9657734 |
1998 |
|
Sentinel node (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, hypermethylation of GSTP1 and/or RAR-beta2 was significantly associated with patients having macroscopic SLN metastasis compared with those with microscopic or no sentinel node metastasis (odds ratio, 4.59; 95% confidence interval, 2.02-10.4; P < 0.001).
|
15788661 |
2005 |
|
Attention deficit hyperactivity disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To test the hypothesis that genetic variants of the retinoid receptor genes may predispose to schizophrenia and other psychiatric diseases, the six RAR and RXR genes and a heterodimer partner, the NURR1 gene, were scanned in 100 schizophrenia patients, along with pilot studies in 20-24 patients with bipolar disorder (BPD), attention-deficit hyperactivity disorder (ADHD), autism, or alcoholism.
|
15635645 |
2005 |
|
Congenital absence of kidneys syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic investigations have identified several gene variants that cause RA, including <i>EYA1</i>, <i>LHX1</i>, and <i>WT1</i> However, whereas compound null mutations of genes encoding α and γ retinoic acid receptors (RARs) cause RA in mice, to date there have been no reports of variants in RAR genes causing RA in humans.
|
28739660 |
2017 |
|
RENAL ADYSPLASIA
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic investigations have identified several gene variants that cause RA, including <i>EYA1</i>, <i>LHX1</i>, and <i>WT1</i> However, whereas compound null mutations of genes encoding α and γ retinoic acid receptors (RARs) cause RA in mice, to date there have been no reports of variants in RAR genes causing RA in humans.
|
28739660 |
2017 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.
|
16504291 |
2006 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Multivariate Cox regression analysis identified 7 factors that independently predicted short survival in t-MDS: age ≥ 65 years (hazard ratio [HR], 1.63), Eastern Cooperative Oncology Group performance status 2-4 (HR, 1.86), poor cytogenetics (-7 and/or complex; HR, 2.47), World Health Organization MDS subtype (RARs or RAEB-1/2; HR, 1.92), hemoglobin (< 11 g/dL; HR, 2.24), platelets (< 50 × 10(9)/dL; HR, 2.01), and transfusion dependency (HR, 1.59).
|
24875590 |
2014 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, subsequent basic and clinical studies showed that chromosomal translocation involving the RARalpha gene is the cytogenetic hallmark of APL and that these mutant forms of RARs are the oncogenes in APL that interfere with the proliferation and differentiation pathways controlled by both RAR and their fusion partners.
|
11704848 |
2001 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Southern genomic analysis demonstrated re-arrangements of the retinoic acid receptor varies; is directly proportional to (RAR varies; is directly proportional to) and PML genes in the APL blasts at presentation but not in the M2 ANLL marrow at relapse.
|
7832190 |
1995 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RARA sequences are the same as the RARA sequences found in the PML-RAR and PLZF-RAR fusion seen in t(15;17) and t(11;17) APL, respectively.
|
8562957 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAR-beta2 re-expression causes reversal of transformation, cell cycle arrest, and restoration of retinoid sensitivity.RAR-beta2 is thus a tumor suppressor.
|
15766561 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A growing body of evidence supports the hypotheses that retinoic acid receptor beta2 (RAR beta2) is a tumor suppressor gene.
|
11141504 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A growing body of evidence supports the hypothesis that the retinoic acid receptor beta2 (RAR-beta2) gene is a tumor suppressor gene which induces apoptosis and that the chemopreventive and therapeutic effects of retinoids are due to induction of RAR-beta2.
|
11501579 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of RARbeta protein in 15 breast carcinoma patients harboring unmethylated RAR bin tumors and serum DNA showed the expression of RARbeta protein in tumors and paired normal breast tissues, confirming the MSP findings, suggesting that RARbeta promoter is functional in these cases.
|
17998817 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In ALDH<sup>+</sup>CD24<sup>-</sup>CD44<sup>+</sup> BCSCs, we identified P4HA2, PTGR1 and RAB40B as potential prognostic markers, which were virtually related to the status of BCSCs and tumor growth in TNBC cells.
|
29471829 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAR-beta2, one of three human RAR-beta isoforms (RAR-beta1, RAR-beta2, RAR-beta4), is silenced in many tumors and acts as a tumor suppressor.
|
17608728 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the three RAR receptors (alpha, beta, and gamma), RARbeta has been considered a tumor suppressor gene.
|
15604252 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative methylation-specific PCR (qMSP) was performed using a selected tumor-related gene panel for RAR-ss2, MGMT, RASSF1A, and APC.
|
17108214 |
2006 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
The methylation rate of RAR-β2 in breast cancer and precancerous lesions of breast cancer were higher than that of normal tissues.
|
20865461 |
2011 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrate that Rab40b is also required for breast cancer cell invasion in vitro.
|
23902685 |
2013 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
Five lines of evidence suggest that melatonin works via epigenetic processes: (1) melatonin influences transcriptional activity of nuclear receptors (ERalpha, GR and RAR) involved in the regulation of breast cancer cell growth; (2) melatonin down-regulates the expression of genes responsible for the local synthesis or activation of estrogens including aromatase, an effect which may be mediated by methylation of the CYP19 gene or deacetylation of CYP19 histones; (3) melatonin inhibits telomerase activity and expression induced by either natural estrogens or xenoestrogens; (4) melatonin modulates the cell cycle through the inhibition of cyclin D1 expression; (5) melatonin influences circadian rhythm disturbances dependent on alterations of the light/dark cycle (i.e., light at night) with the subsequent deregulation of PER2 which acts as a tumor suppressor gene.
|
18592373 |
2009 |